Evidence map›Paper›PMID 34496556›Full record

ArticleTurkish journal of pharmaceutical sciences2021

Preparation and Characterization of Mucoadhesive Loratadine Nanoliposomes for Intranasal Administration

Lena Tamaddon, Negar Mohamadi, Neda Bavarsad

Abstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Preparation and in vitro Immunoreactivity ofIranian journal of pharmaceutical research : IJPR
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lena TamaddonDepartment of Pharmaceutics, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranORCID 0000-0002-6052-2754
Negar MohamadiDepartment of Pharmaceutics, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranORCID 0000-0002-7460-1322
Neda BavarsadDepartment of Pharmaceutics, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranORCID 0000-0002-7872-0273

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The present study aimed to formulate and characterize mucoadhesive liposomes for intranasal delivery of loratadine. In particular, the formulation was aimed to improve the drug bioavailability and efficacy. Materials and Methods: Liposomes were prepared by thin-film hydration method, with soybean phosphatidylcholine and cholesterol as main components. Liposomes were coated with chitosan solution at a concentration of 0.05% and 0.1%, w/v. The formulations were assessed for particle size, polydispersity index (PDI), encapsulation efficiency (EE), thermodynamic behavior, Results: Particle size analysis showed that the vesicles of uncoated and coated liposomes with 0.05% and 0.1% chitosan were characterized by size of 193±3.3 nm, 345±4.6, and 438±7.3 nm, respectively. Size distribution for developed formulations was in the acceptable range (PDI <0.7). EE was recorded to be approximately 80%. Chitosan-coated liposomes demonstrated slower release rate as compared to uncoated liposomes. Drug release kinetics profile for all the formulations followed a zero-order model. Chitosan coating improved mucoadhesiveness by more than 3-fold as compared to uncoated liposomes. However, no significant differences were recorded between mucin adsorption behavior of 0.05% and 0.1% chitosan-coated liposomes (p>0.05). For stability studies, liposomes were stored at 4°C for 3 months, and changes in particle diameter, PDI, and EE % were recorded. No significant alternations were reported in particles size, PDI, and drug leakage of coated liposomes. Conclusion: Liposomes coated with 0.05% chitosan were chosen as the optimum formulation, which demonstrated a significant potential for overcoming the nasal drug delivery limits for short residence time and mucociliary clearance.

Indexed as

chitosanintranasalLiposomesloratadinemucoadhesive

Identifiers

PMID34496556
PMCPMC8430403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.